hydroxyurea has been researched along with paclitaxel in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 16 (31.37) | 18.2507 |
| 2000's | 22 (43.14) | 29.6817 |
| 2010's | 12 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ajani, JA; Baker, FL; Brock, WA; Fan, D; Spitzer, G; Tomasovic, B | 1 |
| Haraf, DJ; Levin, J; Malone, D; Stenson, K; Stupp, R; Vokes, EE; Weichselbaum, RR | 1 |
| Aisner, J; Belani, CP; Conley, B; Gray, W; Hiponia, D; Jacobs, M | 1 |
| Haraf, D; Malone, D; Moran, W; Stupp, R; Sweeney, P; Vokes, EE; Weichselbaum, RR; Wenig, B | 1 |
| Brelje, TC; Parsons, JA; Sorenson, RL | 1 |
| Dulude, H; Evans, WK; Gertler, SZ; Goss, G; Huan, S; Logan, D; Stewart, DJ; Tomiak, EM; Yau, J | 1 |
| Andreassen, PR; Lacroix, FB; Margolis, RL; Trielli, MO | 1 |
| Cannistra, SA; Korsmeyer, S; Strobel, T; Swanson, L | 1 |
| Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Brockstein, B; Fasanmade, A; Glisson, B; Haraf, DJ; Klepsch, A; Lippman, SM; Ratain, MJ; Stenson, K; Stupp, R; Sulzen, L; Vokes, EE; Weichselbaum, RR | 1 |
| Durka, S; Hueber, A; Weller, M | 1 |
| Balczon, R; Schroer, TA; Varden, CE | 1 |
| Brockstein, BE; Haraf, DJ; Vokes, EE; Weichselbaum, RR | 1 |
| Chen, J; Donovan, S; Hong, FD; Nisen, PD; Schneider, N | 1 |
| Ariizumi, T; Asashima, M; Tamai, K; Yokota, C | 1 |
| Fan, W; Johnson, KR; Young, KK | 1 |
| Denoulet, P; Desbruyères, E; Eddé, B; Regnard, C | 1 |
| Hsu, CP; Yang, CC; Yang, SD | 1 |
| Brockstein, B; Haraf, DJ; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RW; Witt, ME | 1 |
| Doroshenko, N; Doroshenko, P; Sabanov, V | 1 |
| Brockstein, B; Chung, T; Haraf, DJ; Kies, MS; List, M; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, A; Rosen, F; Stenson, K; Vokes, EE; Weichselbaum, R | 1 |
| Goehle, S; Lamb, JR; Ludlow, C; Simon, JA | 1 |
| Brockstein, BE; Fung, BB; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Remlinger, KA | 1 |
| Brockstein, BE; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Chung, MK; Han, SS; Kim, EJ; Kim, JE; Kim, SN; Koh, WS; Kwon, J; Lee, M; Song, CW | 1 |
| Argiris, A; Brockstein, BE; Haraf, DJ; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Chua, ET; Goh, BC; Hsieh, WS; Lim, HL; Loh, KS; Lu, JJ; Shakespeare, TP; Soo, RA; Tan, KS; Wong, AS | 1 |
| Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J | 1 |
| Cohen, EE; Haraf, DJ; Knab, BR; Salama, JK; Solanki, A; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Argiris, A; Brockstein, BE; Cohen, EE; Haraf, DJ; Kistner, EO; Mittal, BB; Rosen, F; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Conklin, DS; Hergert, P; Khodjakov, A; Kourtidis, A; Loncarek, J; O'Connell, CB | 1 |
| Johnson, MK; Wise, DA | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Gong, Y; Guo, H; Jiang, H; Liu, Q; Liu, Z; Shao, C; Sun, Z; Tischfield, JA; Xu, B; Zou, Y | 1 |
| Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME | 1 |
| Blair, EA; Cohen, EEW; Haraf, DJ; List, M; Mouw, KW; Salama, JK; Solanki, AA; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Azad, N; Iyer, AK; Kaushik, V; Kulkarni, Y; O'Doherty, GA; Venkatadri, R; Wright, C; Yakisich, JS | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
5 review(s) available for hydroxyurea and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Tumor Cells, Cultured | 1995 |
Combined modalities in the treatment of head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Hydroxyurea; Methotrexate; Paclitaxel; Platinum Compounds | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Infusions, Intravenous; Paclitaxel | 1995 |
Cutaneous reactions to chemotherapy drugs: the art of consultation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Docetaxel; Doxorubicin; Drug Eruptions; Humans; Hydroxyurea; Paclitaxel; Skin; Taxoids; Thalidomide | 2003 |
11 trial(s) available for hydroxyurea and paclitaxel
| Article | Year |
|---|---|
Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydroxyurea; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1997 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Prognosis | 1998 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Prognosis; Recombinant Proteins | 2000 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Illinois; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2001 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Erythropoietin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Rate; Treatment Outcome | 2003 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2004 |
Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Hydroxyurea; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Survival Analysis; Treatment Failure | 2006 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction | 2008 |
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Female; Fluorouracil; Humans; Hydroxyurea; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Risk Factors; Time Factors; Treatment Outcome | 2012 |
35 other study(ies) available for hydroxyurea and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Hydroxyurea; Organometallic Compounds; Paclitaxel; Spiro Compounds; Tumor Cells, Cultured | 1987 |
Regulation of islet beta-cell proliferation by prolactin in rat islets.
Topics: Alkynes; Analysis of Variance; Animals; Animals, Newborn; Cell Division; Cells, Cultured; Colchicine; Diamines; Eflornithine; Hydroxyurea; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Ornithine Decarboxylase Inhibitors; Paclitaxel; Prolactin; Rats; Rats, Sprague-Dawley; Time Factors | 1994 |
Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells.
Topics: Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Phytogenic; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Line; Cell Line, Transformed; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Fibroblasts; G1 Phase; Humans; Hydroxyurea; Microtubule-Associated Proteins; Microtubules; Nocodazole; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Rats; Retinoblastoma Protein; Simian virus 40; Tumor Suppressor Proteins | 1996 |
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carboplatin; Cell Cycle; Cell Line; Cell Survival; Etoposide; Female; Humans; Hydroxyurea; Immunoblotting; Kinetics; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53; Vincristine | 1996 |
CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aphidicolin; Apoptosis; Camptothecin; Cell Cycle; Cell Death; Cisplatin; Culture Media, Serum-Free; Doxorubicin; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Gene Expression; HeLa Cells; Humans; Hydroxyurea; Jurkat Cells; Membrane Glycoproteins; Nimustine; Nocodazole; Paclitaxel; Sensitivity and Specificity; Teniposide; Tumor Cells, Cultured; Vincristine | 1998 |
Role for microtubules in centrosome doubling in Chinese hamster ovary cells.
Topics: Animals; Centrosome; CHO Cells; Cricetinae; Dynactin Complex; Dyneins; Hydroxyurea; Immunoblotting; In Vitro Techniques; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Mitosis; Nocodazole; Paclitaxel; Spindle Apparatus; Time Factors; Tubulin | 1999 |
Taxol, vincristine or nocodazole induces lethality in G1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression.
Topics: Astrocytoma; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Enzyme Inhibitors; Fibroblasts; Flow Cytometry; Humans; Hydroxyurea; Karyotyping; Microtubule-Associated Proteins; Nocodazole; Paclitaxel; Phosphorylation; Polyploidy; Retinoblastoma Protein; Thymidine; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vincristine | 1999 |
Cytochalasin B inhibits morphogenetic movement and muscle differentiation of activin-treated ectoderm in Xenopus.
Topics: Actin Cytoskeleton; Activins; Animals; Aphidicolin; Cell Differentiation; Cell Movement; Colchicine; Culture Techniques; Cytochalasin B; Ectoderm; Embryo, Nonmammalian; Embryonic Induction; Gene Expression; Hydroxyurea; Inhibins; Morphogenesis; Muscles; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Xenopus | 1999 |
Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Administration Schedule; Fluorouracil; G1 Phase; Humans; Hydroxyurea; KB Cells; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; S Phase; Tumor Cells, Cultured | 1999 |
Tubulin polyglutamylase: isozymic variants and regulation during the cell cycle in HeLa cells.
Topics: Animals; Brain; Cell Cycle; Cell Division; Centrioles; Docetaxel; G2 Phase; Gene Expression Regulation, Enzymologic; Genetic Variation; HeLa Cells; Humans; Hydroxyurea; Isoenzymes; Mice; Nocodazole; Paclitaxel; Peptide Synthases; Polyglutamic Acid; Spindle Apparatus; Taxoids; Tubulin | 1999 |
Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; DNA, Antisense; DNA, Complementary; DNA, Recombinant; Dose-Response Relationship, Drug; Fluorouracil; Gene Expression Regulation, Enzymologic; Genetic Vectors; Humans; Hydroxyurea; Male; Paclitaxel; Proline-Directed Protein Kinases; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Transfection; Tumor Cells, Cultured | 2000 |
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
Topics: Animals; Aphidicolin; Cell Cycle; Cell Division; Cell Line; Cell Size; Chlorides; Culture Media, Serum-Free; Cytarabine; Electric Conductivity; Enzyme Inhibitors; Fibroblasts; Hydroxyurea; Ion Transport; Lovastatin; Mice; Mimosine; Osmotic Pressure; Paclitaxel; Patch-Clamp Techniques | 2001 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms; Colony-Forming Units Assay; Cricetinae; Drug Screening Assays, Antitumor; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Thymidine; Tritium; Tumor Cells, Cultured | 2001 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Lymph Nodes; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
cDNA microarray gene expression profiling of hydroxyurea, paclitaxel, and p-anisidine, genotoxic compounds with differing tumorigenicity results.
Topics: Aniline Compounds; Animals; DNA Damage; Gene Expression Profiling; Hydroxyurea; Lymphoma; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Tumor Cells, Cultured | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate | 2003 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Estradiol; Flow Cytometry; Fulvestrant; Humans; Hydroxyurea; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Paclitaxel; Purines; RNA, Small Interfering; Roscovitine; Spindle Apparatus; Survivin; Thymidine; Transfection | 2007 |
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hydroxyurea; Immunohistochemistry; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organ Preservation; Paclitaxel; Probability; Quality of Life; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
The spindle assembly checkpoint is satisfied in the absence of interkinetochore tension during mitosis with unreplicated genomes.
Topics: Anaphase; Autoantigens; Calcium-Binding Proteins; Cell Cycle Proteins; Centromere Protein A; Chromatin; Chromosomal Proteins, Non-Histone; DNA Replication; Enzyme Inhibitors; Genome, Human; HeLa Cells; Humans; Hydroxyurea; Indoles; Kinetics; Kinetochores; Mad2 Proteins; Metaphase; Microscopy, Electron; Microtubules; Mitosis; Nocodazole; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Pyrimidines; Repressor Proteins; Spindle Apparatus; Sulfonamides; Thiones | 2008 |
Distribution of kinetochore fragments during mitosis with unreplicated genomes.
Topics: Anaphase; Animals; Centromere; CHO Cells; Chromosomal Proteins, Non-Histone; Cricetinae; Cricetulus; Genome; Hydroxyurea; Kinetochores; Microscopy, Confocal; Microtubules; Mitosis; Paclitaxel; Spindle Apparatus | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks.
Topics: Animals; Aphidicolin; Cell Line; DNA Breaks, Double-Stranded; DNA Replication; Histones; Humans; Hydroxyurea; Mice; Micronuclei, Chromosome-Defective; Mutation; Paclitaxel; Replication Protein A; RNA, Small Interfering; S Phase; Stress, Physiological; Thymidine | 2011 |
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salivary Gland Neoplasms; Treatment Outcome | 2011 |
Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digitoxin; Drug Synergism; Hexoses; Humans; Hydroxyurea; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |